Shanghai RAAS(SZ:002252)2023-06-14 13:10Group 1: Company Overview - Shanghai Laishi Blood Products Co., Ltd. is a leading enterprise in the domestic blood products industry, with a comprehensive product range and high plasma utilization rate [2][3]. - The company has four production bases located in Shanghai, Zhengzhou, Hefei, and Wenzhou, and operates 42 plasma collection stations across 11 provinces [3][4]. Group 2: Share Buyback Plan - The company plans to repurchase shares with a total fund amount of no less than RMB 500 million and not exceeding RMB 1 billion, with a repurchase price not exceeding RMB 8.00 per share [3][4]. - Of the repurchased shares, 30% will be used for cancellation to reduce registered capital, while 70% will be used for employee stock ownership plans [3]. Group 3: Future Development and Production Trends - The company aims to enhance plasma collection through better management of existing stations and the establishment of new ones, with annual collection volume disclosed in future reports [3][4]. - Zhengzhou Laishi, which resumed production in December 2021, is expected to stabilize its capacity, yield, sales revenue, and profit margins within 2-3 years [4][5]. Group 4: Financial Performance and Dividends - In June 2023, the company announced a cash dividend of RMB 0.30 per share, based on a total share capital of 6,740,787,907 shares [3][4]. - The company reported a 17% year-on-year increase in plasma collection volume in 2022, with stable production and sales of existing products [4][5]. Group 5: Strategic Partnerships - The company has a strategic cooperation agreement with GDS, focusing on quality management, technology research and development, and sales channels, which positively impacts its operations [4][5]. - GDS has achieved a cumulative EBITDA of USD 1.141 billion from 2019 to 2022, with an average annual EBITDA of USD 285 million [5].